Greenwich LifeSciences Inc
GLSIBuild a strategy around GLSI
Greenwich LifeSciences Inc AI Insights
Informational only. Not investment advice.Snapshot
- Zero revenue pre-clinical biotech with 3.8M cash vs 8.6M TTM burn rate - under 6 months runway without dilution[Cash and Equivalents / Free Cash Flow TTM]
- P/B of 63x on 2.2M equity - market pricing in 134M EV on binary clinical trial outcome alone[P/B Ratio]
- R&D spend of 15.8M TTM is 81% of opex - focused capital deployment on core asset GP2 vaccine[Research and Development TTM]
Watch Triggers
- Cash and Equivalents: Falls below 2M or new equity filing announced — Signals imminent dilution timing and potential pricing pressure
- Research and Development TTM: Significant increase or decrease from 15.8M run rate — Indicates Phase III trial progression or wind-down
- Total Revenue TTM: Any non-zero revenue or partnership income — Would signal licensing deal or milestone payment - thesis changing
Bull Case
GP2 breast cancer vaccine in Phase III - positive data could justify 10-50x current EV given addressable market. Zero debt provides clean balance sheet for partnership deals.
81% R&D allocation shows disciplined focus on single high-conviction asset vs scattered pipeline risk typical of small biotechs.
Bear Case
Sub-6-month cash runway guarantees near-term dilution. At current burn, need 8-10M annually - 6-7% dilution minimum at current market cap.
Binary outcome risk: 63x P/B prices in success. Trial failure = equity near zero. No revenue diversification or asset optionality.
Bull vs Bear Balance
AI-generated sentiment analysis based on fundamental metrics and market conditions.
Leverage GLSI's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.
Forward Thesis
Imminent capital raise required within 6 months - dilution or partnership announcement likely catalyst
- 3.8M cash vs 8.6M annual burn
- Zero debt capacity on 2.2M equity
- 3.2M raised TTM via stock issuance
Valuation Context
Caveats
GLSI Fundamentals
| Metric | Value | YoY Growth | Industry Percentile |
|---|---|---|---|
$370.91M | — | ||
$367.1M | — | ||
0.00 | — | ||
$0 | — | ||
$-1.46 | — | ||
0% | 0.0% | — | |
0% | 0.0% | — | |
$-8.59M | — | ||
-543% | -391.7% | — | |
Beta 5Y (Monthly) | unknown | — |
GLSI Dividend History
GLSI Stock Splits
GLSI SEC Filings
| Filing Date | Report Date | Report Type | Filing Link |
|---|---|---|---|
11/14/25 | 09/30/25 | 10-Q | |
08/14/25 | 06/30/25 | 10-Q | |
05/20/25 | 03/31/25 | 10-Q | |
04/15/25 | 12/31/24 | Unknown | |
11/14/24 | 09/30/24 | 10-Q | |
08/14/24 | 06/30/24 | 10-Q | |
05/20/24 | 03/31/24 | 10-Q | |
04/15/24 | 12/31/23 | 10-K | |
10/19/23 | 09/30/23 | 10-Q | |
08/21/23 | 06/30/23 | 10-Q | |
05/22/23 | 03/31/23 | 10-Q | |
03/31/23 | 12/31/22 | 10-K | |
11/14/22 | 09/30/22 | 10-Q | |
08/15/22 | 06/30/22 | 10-Q | |
05/20/22 | 03/31/22 | 10-Q | |
03/21/22 | 12/31/21 | 10-K | |
11/15/21 | 09/30/21 | 10-Q | |
08/13/21 | 06/30/21 | 10-Q | |
05/20/21 | 03/31/21 | 10-Q | |
03/31/21 | 12/31/20 | 10-K | |
11/16/20 | 09/30/20 | 10-Q | |
09/28/20 | 06/30/20 | 424B4 | |
05/20/21 | 03/31/20 | 10-Q | |
09/28/20 | 12/31/19 | 424B4 | |
11/16/20 | 09/30/19 | 10-Q | |
09/28/20 | 06/30/19 | 424B4 |